Open Forum Infectious Diseases

Papers
(The H4-Index of Open Forum Infectious Diseases is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-09-01 to 2024-09-01.)
ArticleCitations
Monkeypox: A Contemporary Review for Healthcare Professionals164
Long COVID and Post-infective Fatigue Syndrome: A Review143
Postacute COVID-19: An Overview and Approach to Classification129
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19123
Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019102
Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections101
Prevalence and Healthcare Burden of Fungal Infections in the United States, 201887
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia86
Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study84
Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms81
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients80
Coronavirus Disease 2019–Associated Invasive Fungal Infection79
Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study77
Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States72
Transmission of SARS-CoV-2 in Public Transportation Vehicles: A Case Study in Hunan Province, China72
Sources of Vaccine Hesitancy: Pregnancy, Infertility, Minority Concerns, and General Skepticism71
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis68
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era64
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response62
Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement60
Risk of Clinical Severity by Age and Race/Ethnicity Among Adults Hospitalized for COVID-19—United States, March–September 202059
The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study59
CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants59
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar56
Sexually Transmitted Infection Diagnoses and Access to a Sexual Health Service Before and After the National Lockdown for COVID-19 in Melbourne, Australia56
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection56
A Distinct Phylogenetic Cluster of Indian Severe Acute Respiratory Syndrome Coronavirus 2 Isolates55
Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series55
SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response54
The Protective Effect of Coronavirus Disease 2019 (COVID-19) Vaccination on Postacute Sequelae of COVID-19: A Multicenter Study From a Large National Health Research Network54
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients54
Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter spp, Citrobacter freundii, Morganella mor53
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease52
The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries51
Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies50
Fungal Nomenclature: Managing Change is the Name of the Game50
Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients49
Economic Burden of Fungal Diseases in the United States48
Long-Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-up Cohort Study48
The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study48
Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria47
Global Seasonality of Human Coronaviruses: A Systematic Review46
Cefiderocol Activity Against ClinicalPseudomonas aeruginosaIsolates Exhibiting Ceftolozane-Tazobactam Resistance46
Social Determinants of Health and Care Outcomes Among People With HIV in the United States46
Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-1944
Persistent Symptoms in Patients Recovering From COVID-19 in Denmark44
Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine44
Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials44
Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study44
0.10949301719666